STACK · ↗ Additive ladder · 4 tiers
Metabolic Health.
Insulin sensitivity, cellular energy, mitochondrial fuel choice.
Hook facts
The science, in one line each.
MOTS-c is banned in competitive sports by WADA — which means regulators already consider it performance-enhancing enough to prohibit. It's essentially a molecular signal your mitochondria normally send during intense exercise, now available as an injection.
When to skip it
Read this first.
This stack is not designed for rapid weight loss or appetite suppression — those goals are better served by the Weight Loss stack. Not appropriate for individuals with active liver disease without physician oversight, as NNMT plays roles in hepatic metabolism. Anyone under 25 with intact metabolic signalling will see limited incremental benefit. This stack works on metabolic reprogramming timelines of weeks to months — not the right choice for anyone expecting dramatic short-term body composition change.
Always cleared with your concierge before protocol start.
Why this works
The strongest evidence.
MOTS-c is one of the most well-validated mitochondrial peptides in the metabolic literature — encoded directly in mitochondrial DNA, it has demonstrated AMPK activation, insulin-independent glucose uptake improvement, and exercise-mimetic effects in both animal models and early human studies (Lee et al., Cell Metabolism, 2015; Zarse & Ristow, Cell Metabolism, 2015). 5-Amino-1MQ has striking preclinical data: in one obese mouse study, NNMT inhibition caused a 47% reduction in fat mass, with subjects reaching body composition and liver adiposity parameters comparable to lean controls — while a separate study showed serum insulin reductions of 50–60% and significantly decreased adipocyte size, triglycerides, and free fatty acids (Kraus et al., Cell Metabolism; Hong et al., Nature Medicine). SS-31 (elamipretide) has the strongest translational evidence of any compound in this stack, with multiple Phase 2/3 trials in heart failure and Barth syndrome establishing its cardiolipin-binding mechanism and mitochondrial protection profile in humans.
Additive ladder
Choose your tier.
Each tier builds on the last. Start where you are — add depth as your goals evolve.
Insulin Sensitivity
MOTS-c
The entry point for anyone with fasting glucose concerns, insulin resistance markers, metabolic syndrome flags, or post-…
MOTS-c is encoded inside mitochondrial DNA itself — your body's own metabolic master signal. It activates AMPK, the cellular switch that controls whether skeletal muscle burns fat or stores glucose, and restores insulin-independent glucose uptake that declines with age and inactivity. If your fasting glucose is creeping up, your post-meal energy is crashing, or you're training consistently but not shifting body composition, this is the signal that's degraded. Foundation tier is the single-agent protocol for restoring it.
Who it's for
Pre-diabetes, metabolic syndrome flags, or the post-40 'sluggish despite training' pattern. The single-agent entry for anyone wanting to restore metabolic signalling without complexity. Fasting glucose above 95 mg/dL, declining VO2max, or poor insulin response on blood work are all indicators that MOTS-c alone is the right starting point.
What to expect
Reduced afternoon fatigue and improved exercise endurance within 2 weeks. Fasting glucose and insulin sensitivity markers measurably improved by week 6. Users with pre-diabetes patterns often see the clearest signal at this tier — MOTS-c's insulin-independent glucose uptake effect is most visible when baseline insulin sensitivity is compromised.
Metabolic Reset
MOTS-c
The entry point for anyone with fasting glucose concerns, insulin resistance markers, metabolic syndrome flags, or post-…
NAD+ 300
Users with energy depletion, age-related metabolic slowdown, or sirtuin-depletion patterns. Composes directly on top of…
MOTS-c sends the AMPK signal; NAD+ provides the fuel that signal runs on. Sirtuin enzymes — SIRT1, SIRT3 — are the downstream executors of the metabolic programme MOTS-c activates, and they require NAD+ as substrate. Levels fall by up to 50% between your 20s and 50s. This is why adding NAD-300 on top of MOTS-c is additive rather than duplicative: the signal is already there, but without cofactor, the enzymes that should act on it are running on empty. Standard tier restores both the upstream switch and the biochemical fuel.
Who it's for
Users who have addressed the AMPK signal with MOTS-c but still have energy depletion, age-related sirtuin decline, or HbA1c that hasn't fully normalised. The classic AMPK + sirtuin pairing — most clinical metabolic protocols sit here. Adding NAD+ is not redundant: MOTS-c activates the switch, but the downstream enzymes (SIRT1, SIRT3) that execute the metabolic programme are NAD+-dependent. One without the other leaves the signal running on a depleted substrate.
What to expect
MOTS-c + NAD+ compound by week 4 into meaningfully better training performance and glucose regulation. Metabolic flexibility improvements — fat oxidation vs glucose dependence shift — typically measurable by week 8 in users who are also doing resistance training. Sirtuin-mediated benefits (cellular repair, mitochondrial biogenesis) build over the full 12-week cycle.
Full Metabolic Stack
MOTS-c
The entry point for anyone with fasting glucose concerns, insulin resistance markers, metabolic syndrome flags, or post-…
NAD+ 300
Users with energy depletion, age-related metabolic slowdown, or sirtuin-depletion patterns. Composes directly on top of…
5-Amino 1MQ
Users who have addressed the mitochondrial and sirtuin axes (MOTS-c + NAD+) but still carry metabolic stiffness — viscer…
MOTS-c and NAD+ work on the mitochondrial and muscular axes — they're the engine and the fuel. 5-Amino-1MQ operates on a third axis entirely: it inhibits NNMT in adipocytes, the enzyme that suppresses fat-cell metabolism and blocks NAD+ precursor recycling in stored fat. NNMT activity rises with age and obesity, creating a brake that keeps fat cells metabolically inert even when every other signal says burn. 1MQ removes that brake. Mouse models show 47% fat mass reduction over 11 days at metabolic doses with no change in food intake — the effect is purely metabolic, not appetite-mediated. Full Metabolic Stack: AMPK signal, sirtuin substrate, adipocyte brake removal.
Who it's for
Users running the full metabolic-flexibility protocol. 5-Amino-1MQ adds what MOTS-c and NAD+ cannot: adipocyte-level NNMT inhibition. NNMT is the enzyme that degrades NAD+ precursors in fat cells and suppresses their ability to oxidise stored lipids — it's the metabolic brake that keeps visceral and subcutaneous fat stubborn even when the mitochondrial axis is optimised. Users with persistent central adiposity, post-GLP-1 metabolic stiffness, or insulin resistance that hasn't fully resolved at Standard tier are the primary candidates.
What to expect
Mouse models of NNMT inhibition show 47% fat mass reduction with no change in food intake — pure metabolic effect. Human users report improved fat oxidation, reduced metabolic sluggishness, and clearer insulin response by week 4–6. The 1MQ contribution is most visible in adipocyte-specific outcomes: visceral fat reduction and post-meal insulin response improvement that the mitochondrial-axis compounds alone don't produce.
Mitochondrial Protection
+ sits on top of any tier above
SS-31
Users with high oxidative load — chronic illness recovery, heavy endurance training, post-illness fatigue, or metabolic…
MOTS-c, NAD+, and 1MQ are loading the metabolic engine — AMPK activation, sirtuin substrate, adipocyte fat release. SS-31 protects the machinery they're depending on. It binds cardiolipin on the inner mitochondrial membrane, stabilises the electron transport chain, and scavenges reactive oxygen species at their source rather than downstream. When oxidative load is high — post-illness, heavy training blocks, metabolic syndrome recovery — the mitochondria taking on that load are the same ones the rest of this stack is driving hard. SS-31 keeps the substrate intact. Multiple Phase 2/3 clinical trials validate the mechanism; this is the adjunct tier when the protection is warranted.
Who it's for
Users with high oxidative-load patterns: chronic illness recovery, heavy endurance training, post-illness fatigue, or metabolic syndrome with elevated inflammatory markers. SS-31 provides mitochondrial membrane protection that the other three compounds don't directly address — they drive signalling and fuel mobilisation; SS-31 protects the mitochondrial substrate they're loading. Users running this stack post-illness or alongside aggressive training are the clearest candidates. Cross-stacks with Cardiac and Longevity Mito.
What to expect
Reduced post-exertion oxidative stress and faster mitochondrial recovery. Most noticeable in endurance athletes and post-illness users as improved resilience to high-demand sessions. The adjunct framing is accurate — SS-31 is a 12-week pulse, not a continuous addition. Run it when oxidative load is high; cycle off when it isn't.
Compound roster
Every compound, briefed.
Each compound in this stack — what it does and where it fits.
A peptide encoded directly inside mitochondrial DNA — the only peptide of its kind in the human genome. MOTS-c acts as a retrograde signal from mitochondria to the nucleus and peripheral tissues, activating AMPK (the master metabolic switch) in skeletal muscle and liver. AMPK activation restores insulin-independent glucose uptake, shifts fuel preference toward fat oxidation, and produces an exercise-mimetic metabolic effect even at rest. It is the foundational compound of this stack: the upstream signal that everything else composes on top of.
Best for · The entry point for anyone with fasting glucose concerns, insulin resistance markers, metabolic syndrome flags, or post-40 metabolic slowdown. Anchors every tier in this stack.
NAD+ (nicotinamide adenine dinucleotide) is the redox cofactor that mitochondria use to convert nutrients into ATP, and the substrate that sirtuin enzymes (SIRT1, SIRT3) and PARP require to function. NAD+ levels fall measurably with age — by middle age, tissue NAD+ can be 50% below youthful levels. This matters here specifically because MOTS-c's AMPK signal feeds into the SIRT1 axis: the signal exists, but without adequate NAD+, the downstream enzymes can't act on it. NAD-300 provides that missing substrate directly, giving the mitochondrial signalling network the fuel it needs to translate AMPK activation into metabolic output.
Best for · Users with energy depletion, age-related metabolic slowdown, or sirtuin-depletion patterns. Composes directly on top of MOTS-c — the redox fuel the AMPK signal runs on.
5-Amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase) — the enzyme that degrades NAD+ precursors and suppresses adipocyte metabolism. NNMT activity increases with age and obesity, creating a metabolic brake that prevents fat cells from oxidising stored lipids even when other metabolic signals improve. By inhibiting NNMT, 5-Amino-1MQ reactivates dormant NAD+ biosynthesis pathways in adipocytes and pushes fat cells toward active lipolysis. Critically, this operates at the adipocyte level — it's not a mitochondrial or muscular-axis compound, which is why it adds genuine signal over MOTS-c + NAD+ rather than duplicating their effect.
Best for · Users who have addressed the mitochondrial and sirtuin axes (MOTS-c + NAD+) but still carry metabolic stiffness — visceral fat, poor insulin response, age-related metabolic flexibility decline. The adipocyte-level brake removal.
SS-31 (elamipretide) is a cardiolipin-binding tetrapeptide that stabilises the inner mitochondrial membrane. Cardiolipin is the lipid that anchors the electron transport chain complexes — when it's damaged by oxidative stress, mitochondrial efficiency collapses. SS-31 concentrates in the inner membrane, scavenges reactive oxygen species at their source, and restores the electrochemical gradient that drives ATP synthesis. In this stack's context, SS-31 is the adjunct tier: the other three compounds drive metabolic signalling and fuel mobilisation, while SS-31 protects the mitochondrial substrate they're loading. Multiple Phase 2/3 clinical trials support its mechanism in heart failure and Barth syndrome.
Best for · Users with high oxidative load — chronic illness recovery, heavy endurance training, post-illness fatigue, or metabolic syndrome with elevated inflammatory markers. Adjunct tier that cross-stacks with Cardiac and Longevity Mito.
Humanin is a second mitochondrial-derived peptide (like MOTS-c), encoded in the 16S rRNA region of mitochondrial DNA. It acts primarily through JAK2/STAT3 and IGFBP-3 signalling to exert cytoprotective, anti-apoptotic, and insulin-sensitising effects. Humanin levels decline with age and are inversely correlated with metabolic syndrome severity in observational studies. In this stack, it's a deeper-protocol extension — not required for the core additive ladder, but available for users pursuing comprehensive mitochondrial-derived peptide coverage.
Best for · Advanced users running the full Pro tier who want to add mitochondrial-derived peptide depth beyond MOTS-c, or those with specific insulin resistance patterns where MOTS-c alone has plateaued. Also surfaces in the Longevity Mito stack.
The science
Peer-reviewed findings.
Key research findings from the compounds in this stack.
MOTS-c serum concentration positively correlates with lower-body muscle strength parameters in young adults, and circulating MOTS-c levels are significantly reduced in type 2 diabetes, gestational diabetes, PCOS, obese children, and coronary endothelial dysfunction — establishing it as a metabolic health biomarker
SOURCE · Domin R et al., International Journal of Molecular Sciences 24(19):14951, 2023; Ramanjaneya et al., 2019; multiple studies reviewed in Kong BS et al., Diabetes & Metabolism Journal 47(3):315–324, 2023
In ovariectomized female mice (menopause model), MOTS-c 5 mg/kg i.p. for 5 weeks significantly reduced white adipose and liver fat accumulation, activated brown adipose tissue, and improved insulin sensitivity via AMPK activation — suggesting particular relevance for post-menopausal metabolic decline
SOURCE · Lu H et al., Journal of Molecular Medicine 97:473–85, 2019; reviewed in Alzheimer's Drug Discovery Foundation MOTS-c monograph, 2025
Protocol
How to run it.
Frequency
MOTS-c: 5–10 mg subcutaneous injection, 2–3 times per week. NAD-300: 250–300 mg IV or subcutaneous, 1–2 times per week (or oral NMN/NR as adjunct between sessions). 5-Amino-1MQ: 50–150 mg orally once daily with food. SS-31 (adjunct): 1–5 mg subcutaneous, 3–5 times per week.
Duration
8–12 week primary cycle; metabolic reprogramming benefits compound with consistent use
Timing
MOTS-c on training days or post-exercise to amplify its exercise-mimetic AMPK activation — the compound is more effective when administered proximate to muscular work. NAD+ in the morning or midday. 5-Amino-1MQ in the morning with or before meals. SS-31 (if added) at any time, morning preferred.
Cycling
MOTS-c: continuous at 2–3x weekly, or 2 weeks on / 1 week off. NAD+: loading phase of 2x weekly for 4 weeks, then maintenance 1x weekly indefinitely. 5-Amino-1MQ: 8–12 weeks on, 4 weeks off. SS-31 (adjunct): 12-week pulse cycles when oxidative load is high; not required continuously.
Who it's for
Your profile.
Adults in their 40s and 50s experiencing metabolic slowdown, insulin resistance, or the early markers of metabolic syndrome — elevated fasting glucose, rising HbA1c, stubborn visceral fat, or declining energy despite consistent diet and exercise. This stack is not a weight-loss intervention; it's an upstream metabolic-flexibility protocol for people who suspect that mitochondrial inefficiency, age-related NAD+ depletion, and NNMT dysregulation are the root cause of their plateau. It's particularly well suited for post-GLP-1 metabolic recovery — restoring the cellular machinery that makes fat oxidation efficient after appetite-suppression therapy ends. Biohackers and longevity-focused individuals with confirmed insulin resistance or prediabetes represent the highest-benefit cohort.
Timeline
What to expect.
- 01
Week 1–2
Energy stability is typically the earliest signal — users report reduced afternoon fatigue, more even energy through the day, and improved exercise tolerance within the first two weeks. MOTS-c's AMPK activation effect on glucose disposal begins within days of the first injection. 5-Amino-1MQ begins its NNMT inhibition immediately; early signs include improved post-meal energy and reduced energy crashes after carbohydrate intake.
- 02
Week 6
Body composition shifts become measurable by week 6. Fasting blood glucose and insulin sensitivity markers typically improve — users with elevated baseline fasting glucose often see meaningful reductions. MOTS-c's effect on skeletal muscle glucose uptake is well established by this point, and users training consistently will notice enhanced endurance and recovery. NAD+ replenishment is supporting sirtuin activation by now; improved mitochondrial output and cognitive clarity are common at this stage.
- 03
Week 12
Sustained NNMT inhibition over 12 weeks supports meaningful metabolic flexibility — the ability to switch efficiently between fat and glucose as fuel. Insulin sensitivity improvements can be clinically significant for prediabetic individuals. Mouse models of 5-Amino-1MQ show 47% fat mass reduction over comparable timescales; human users report the stack's benefits feel self-reinforcing at 12 weeks, as improved metabolic efficiency makes exercise more productive and recovery faster. Post-GLP-1 users typically report stable metabolic function without appetite-suppression dependence.
Stacking notes
How this combines.
This stack is built on three distinct metabolic axes that address different nodes in sequence. MOTS-c provides the upstream AMPK signal — it tells mitochondria and skeletal muscle to switch toward fat oxidation and improve glucose disposal, but that signal requires adequate NAD+ to actually do the biochemical work (AMPK activity feeds into the SIRT1/SIRT3 axis, which is NAD+-dependent). NAD-300 provides that redox substrate directly — not a downstream supplement, but the fuel the MOTS-c signal runs on. 5-Amino-1MQ operates at a different level entirely: it inhibits NNMT in adipocytes, removing the metabolic brake that prevents fat cells from oxidising stored fat. Mitochondrial-axis compounds (MOTS-c + NAD+) improve the engine; 1MQ tells the adipocytes to release what's stored. SS-31 adjunct adds a fourth layer — cardiolipin-binding mitochondrial membrane stabilisation that protects the substrate all three compounds are loading. Users with high oxidative load (post-illness, heavy endurance training, metabolic syndrome) benefit most from the adjunct tier.